Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business Update [Yahoo! Finance]
Unicycive Therapeutics, Inc. (UNCY)
Company Research
Source: Yahoo! Finance
Food and Drug Administration (FDA) with a Prescription Drug User Fee Act (PDUFA) target action date of June 29, 2026 Commercial readiness activities ongoing in anticipation of potential commercial launch of OLC in 3Q26 As of March 30, 2026 unaudited cash, cash equivalents, and marketable securities totaled $54.9 million, with expected runway into 2027 LOS ALTOS, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced its financial results for the full year ended December 31, 2025, and provided a business update “This year is shaping up to be pivotal for Unicycive, underscored by the U.S. Food and Drug Administration's acceptance of our New Drug Application resubmission for OLC and the potential for approval and launch later this year,” said Shalabh Gupta, M.D., Chief Executive Officer of Unicycive. “With hyperphosphatemia still uncontrol
Show less
Read more
Impact Snapshot
Event Time:
UNCY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
UNCY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
UNCY alerts
High impacting Unicycive Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
UNCY
News
- Unicycive Therapeutics Announces Full Year 2025 Financial Results and Provides Business UpdateGlobeNewswire
- Unicycive Therapeutics (UNCY) had its "sell (d-)" rating reaffirmed by <a style="font-weight:bold" href="https://weissratings.com/">Weiss Ratings</a>.MarketBeat
- Unicycive Therapeutics (NASDAQ:UNCY) is now covered by analysts at Westpark Capital. They set a "buy" rating on the stock.MarketBeat
- Unicycive Therapeutics to Participate in a Fireside Chat at Guggenheim’s Emerging Outlook: Biotech SummitGlobeNewswire
- Unicycive: 'Buy' Rating On NDA Resubmission OLC And Potential Best-In-Class Profile [Seeking Alpha]Seeking Alpha
UNCY
Sec Filings
- 3/30/26 - Form 8-K
- 3/30/26 - Form 10-K
- 2/17/26 - Form SCHEDULE
- UNCY's page on the SEC website